CAR T cells and dendritic cells: vaccinomics perspectives

Author:

Anurogo DitoORCID

Abstract

Immunotherapy has revolutionized cancer treatment with Chimeric Antigen Receptor (CAR) T cells and dendritic cell-based vaccines showing remarkable efficacy in certain malignancies. This review provides an integrative overview of recent advances and future directions in vaccinomics. A critical aspect of improving efficacy is the integration of CAR T cells and dendritic cell-based therapies to leverage synergistic effects. Personalization of cancer treatment, facilitated by strategies such as HLA typing and antigen selection, is essential for targeting specific tumor antigens and evading immune resistance. The tumor microenvironment plays a crucial role in modulating immune responses and can be targeted to enhance therapy efficacy. Novel adjuvants and immune modulators, such as Toll-like receptor agonists and checkpoint inhibitors, can further improve efficacy and safety. Predictive biomarkers and patient stratification strategies are essential for optimizing candidate selection. Future research should focus on optimizing CAR T cell and dendritic cell-based therapies, developing novel combinational strategies, and advancing gene editing and manufacturing techniques. Expansion to non-cancerous diseases could greatly broaden the impact on public health. Addressing challenges and limitations associated with these therapies can unlock their full potential and revolutionize the treatment of various malignancies and other medical conditions.

Publisher

MedCrave Group Kft.

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3